Nitto Denko Corporation   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Osaka Japan (1918)
Status: No NME R&D (1918)

Organization Overview

First Clinical Trial
2014
NCT02061475
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Nitto Denko Corporation | This trial was conducted by the previous sponsor, Nitto Denko Corporation

Active Ingredients

Drugs in Phase 3 Trials (1)

lidocaine (xylocaine) (1 trial)

Drugs in Phase 2 Trials (2)

Key: Nitto Denko Corporation (1) Acquired (1)

insulin human (humulin) (1 trial)

nd-l02-s0201 (2 trials)

Drugs in Phase 1 Trials (1)

nsv0001 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Fibrosis (Phase 2)

Idiopathic Pulmonary Fibrosis (Phase 2)

Influenza, Human (Phase 1)

Pulmonary Fibrosis (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 4